Cardiff Oncology to Present at Upcoming Investor Conferences in May
Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotechnology company, will present at two investor conferences in May 2024. The first, H.C. Wainwright 2nd Annual BioConnect Investor Conference, will be held at the Nasdaq Headquarters in New York City on May 20, 2024, at 2:30 PM ET. The second, Cowen 5th Annual Oncology Innovation Summit, will be a virtual event on May 29, 2024, at 1:30 PM ET. CEO Mark Erlander will represent Cardiff Oncology in fireside chats at both events. Interested parties can access live webcasts via Cardiff Oncology's website, with replays available post-event.
- Upcoming presentations at high-profile investor conferences in May 2024.
- CEO Mark Erlander will represent the company, potentially bolstering investor confidence.
- Access to live webcasts and replays could increase investor engagement and visibility.
- No new financial or clinical data provided in the press release.
- Lack of substantive updates on the company's pipeline or progress.
- Potential investor expectations unmet if no significant announcements are made.
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present at two upcoming investor conferences in May 2024.
Details of the presentations can be found below.
H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
Location: The Nasdaq Headquarters, New York City
Presenter: Mark Erlander, CEO
Format: Fireside Chat
Date: 05/20/2024
Time: 2:30 PM ET
Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA
Location: Virtual
Presenter: Mark Erlander, CEO
Format: Fireside Chat
Date: 05/29/2024
Time: 1:30 PM ET
Interested parties can register for and access the live webcasts for these conferences by visiting the “Events” section of the Cardiff Oncology website. The webcast replays will be available after the conclusion of the respective presentations.
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.
Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com
Investor Contact:
Kiki Patel, PharmD
Gilmartin Group
332-895-3225
Kiki@gilmartinir.com
Media Contact:
Grace Spencer
Taft Communications
609-583-1151
grace@taftcommunications.com
FAQ
What is the date and location of Cardiff Oncology's presentation at the H.C. Wainwright 2nd Annual BioConnect Investor Conference?
Who will present on behalf of Cardiff Oncology at the upcoming investor conferences in May 2024?
How can interested parties access the live webcasts of Cardiff Oncology's presentations?
When is Cardiff Oncology's presentation at the Cowen 5th Annual Oncology Innovation Summit?
